Motif Bio PLC (LON: MTFB) recently received a number of ratings updates from brokerages and research firms:

  • 6/7/2017 – Motif Bio PLC had its price target lowered by analysts at FinnCap from GBX 125 ($1.59) to GBX 100 ($1.27). They now have a “buy” rating on the stock.
  • 6/5/2017 – Motif Bio PLC had its “speculative buy” rating reaffirmed by analysts at Beaufort Securities. They now have a GBX 110 ($1.40) price target on the stock.
  • 6/2/2017 – Motif Bio PLC had its “corporate” rating reaffirmed by analysts at Northland Securities.
  • 5/30/2017 – Motif Bio PLC had its “buy” rating reaffirmed by analysts at FinnCap. They now have a GBX 125 ($1.59) price target on the stock.
  • 5/8/2017 – Motif Bio PLC had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a GBX 90 ($1.15) price target on the stock.
  • 5/3/2017 – Motif Bio PLC had its “speculative buy” rating reaffirmed by analysts at Beaufort Securities. They now have a GBX 110 ($1.40) price target on the stock.
  • 5/2/2017 – Motif Bio PLC had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a GBX 90 ($1.15) price target on the stock.

Motif Bio PLC (MTFB) opened at 30.75 on Tuesday. The company’s 50-day moving average price is GBX 32.49 and its 200-day moving average price is GBX 27.85. Motif Bio PLC has a 12-month low of GBX 21.44 and a 12-month high of GBX 68.25. The stock’s market cap is GBX 60.23 million.

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related companies with MarketBeat.com's FREE daily email newsletter.